HB-8065™ Hep G2 [HEPG2] is a cell line exhibiting epithelial-like morphology that was isolated from a hepatocellular carcinoma of a 15-year-old, White, male youth with liver cancer. The cell line was deposited by the Wistar Institute and is a suitable transfection host. Expression markers include insulin; insulin-like growth factor II [IGF II].
Product category
Human cells
OrganismHomo sapiens, human
Morphology epithelial-like Tissue Liver DiseaseCarcinoma; Hepatocellular
Applications3D cell culture
Cancer research
High-throughput screening
Toxicology
Product format Frozen Storage conditionsVapor phase of liquid nitrogen
Documentation
BSL 1
ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories [BMBL], U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.
ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.
Required Products
These products are vital for the proper use of this item and have been confirmed as effective in supporting functionality. If you use alternative products, the quality and effectiveness of the item may be affected.
General
Specific applications
These cells are suitable as a transfection host
Characteristics
Growth properties Adherent Derivation HepG2 was derived from a liver hepatocellular carcinoma of a 15 year old Caucasian male. Age 15 years Ethnicity White Gender Male Karyotype modal number = 55 [range = 50 to 60]; has a rearranged chromosome 1 Tumorigenic No;
No, in immunosuppressed mice
Yes, in semisolid medium
Genes expressed alpha-fetoprotein [AFP, alpha fetoprotein]; albumin; alpha2 macroglobulin [alpha-2-macroglobulin]; alpha1 antitrypsin [alpha-1-antitrypsin]; transferrin; alpha1 antichymotrypsin [alpha-1-antichymotrypsin]; haptoglobin; ceruloplasmin; plasminogen, complement [C4]; C3 activator; fibrinogen; alpha1 acid glycoprotein [alpha-1 acid glycoprotein]; alpha2 HS glycoprotein [alpha-2-HS-glycoprotein]; beta lipoprotein [beta-lipoprotein]; retinol binding protein [retinol-binding protein] Expression markers Insulin; insulin-like growth factor II [IGF II] CommentsThe cells express 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities.
The cells demonstrate decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone [oxidative stress].
There is no evidence of a Hepatitis B virus genome in this cell line.
In addition to the hepatocellular carcinoma or hepatoma cell line based on the original publication [PubMed: 6248960], HepG2 is also referred as hepatoblastoma cell line [PubMed: 19751877].
Technical informationATCC Technical Services does not have technical information on patent deposits that are not produced or characterized by ATCC. Additional information can be found in the corresponding patent available from the patent holder or with the U.S. and/or international patent office.
Handling information
Unpacking and storage instructions
- Check all containers for leakage or breakage.
- Remove the frozen cells from the dry ice packaging and immediately place the cells at a temperature below -130°C, preferably in liquid nitrogen vapor, until ready for use.
37°C
Atmosphere95% Air, 5% CO2
Handling procedureTo insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.
- Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid [approximately 2 minutes].
- Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- Transfer the vial contents to a centrifuge tube containing 9.0 mL complete culture medium. and spin at approximately 125 x g for 5 to7 minutes.
- Resuspend cell pellet with the recommended complete medium [see the specific batch information for the culture recommended dilution ratio]. and dispense into a 75 cm2 culture flask. Recommended use of Corning® T-75 flasks [catalog #430641]. It is important to avoid excessive alkalinity of the medium during recovery of the cells. It is suggested that, prior to the addition of the vial contents, the culture vessel containing the complete growth medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH [7.0 to 7.6]. pH [7.0 to 7.6].
- Incubate the culture at 37°C in a suitable incubator. A 5% CO2 in air atmosphere is recommended if using the medium described on this product sheet.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% [w/v] Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed [usually within 5 to 15 minutes].
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. - Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Twice per week
Reagents for cryopreservation Complete growth medium supplemented with 5% [v/v] DMSOQuality control specifications
Mycoplasma contamination Not detected STR profiling
Amelogenin: X,Y
CSF1PO: 10,11
D13S317: 9,13
D16S539: 12,13
D5S818: 11,12
D7S820: 10
THO1: 9
TPOX: 8,9
vWA: 17
History
Depositors Wistar Institute Patent depository
This material was deposited with the ATCC Patent Depository to fulfill U.S. or international patent requirements. This material may not have been produced or characterized by ATCC. As an International Depository Authority [IDA] for patent deposits, ATCC is required to complete viability testing only at time of initial deposit of patent material. Patent deposits are made available on behalf of the Depositor when the pertinent U.S. or international patent is issued, but material may not be used to infringe the patent claims.
Patent number4,393,133
Cross referencesLegal disclaimers
Intended use This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Warranty
The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid. Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.
DisclaimersThis product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.
While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.
This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.
Please see the material transfer agreement [MTA] for further details regarding the use of this product. The MTA is available at www.atcc.org.
DisclosuresThis material is cited in a US and/or international patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Depositor of the party to which the material was furnished.
Images
References
Curated Citations
Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983
Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141
Cuthbert C, et al. Regulation of human apolipoprotein A-I gene expression by gramoxone. J. Biol. Chem. 272: 14954-14960, 1997. PubMed: 9169468
Deleersnyder V, et al. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 71: 697-704, 1997. PubMed: 8985401
Benn J, et al. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J. Virol. 70: 4978-4985, 1996. PubMed: 8764004
View All Curated Citations for this Product